Discontinuation rate and reason for discontinuation after sodium‐glucose cotransporter 2 inhibitor prescription in real clinical practice

Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are novel antidiabetic agents that have advantages of weight loss and prevention of cardiovascular diseases. However, SGLT2i have various side effects. To understand their effectiveness, we analysed patients who had discontinued the use of dapagliflozin, an SGLT2i, 3 months after the initial prescription. We evaluated the discontinuation rate of dapagliflozin and the incidence rate of its side effects.

[1]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. , 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  Hun-Sung Kim,et al.  Proceed with Caution When Using Real World Data and Real World Evidence , 2019, Journal of Korean medical science.

[3]  Hun-Sung Kim,et al.  Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records , 2018, Journal of Korean medical science.

[4]  Won-Young Lee,et al.  Data Analytic Process of a Nationwide Population-Based Study on Obesity Using the National Health Information Database Presented by the National Health Insurance Service 2006–2015 , 2017, Journal of obesity & metabolic syndrome.

[5]  S. Inzucchi,et al.  SGLT2 inhibitors in the management of type 2 diabetes , 2016, Endocrine.

[6]  D. Kohan,et al.  The effect of dapagliflozin on renal function in patients with type 2 diabetes , 2016, Journal of Nephrology.

[7]  Irl B Hirsch,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[9]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[10]  Won Jin Kim,et al.  The Side Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor , 2014 .

[11]  Y. Terauchi,et al.  Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial , 2014, Advances in Therapy.

[12]  J. Gerich,et al.  SGLT2 inhibitors in the treatment of type 2 diabetes. , 2014, Diabetes research and clinical practice.

[13]  G. Bakris,et al.  Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. , 2014, Journal of the American Society of Hypertension : JASH.

[14]  D. Kohan,et al.  Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control , 2013, Kidney international.

[15]  K. Johnsson,et al.  Urinary tract infections in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[16]  D. Matthews,et al.  Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes , 2013, Annals of Internal Medicine.

[17]  G. Bakris,et al.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease , 2013, Diabetes, obesity & metabolism.

[18]  K. Yoon,et al.  [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride]. , 2013, Deutsche medizinische Wochenschrift.

[19]  K. Yoon,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[20]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[21]  R. Henry,et al.  SGLT2 inhibition — a novel strategy for diabetes treatment , 2010, Nature Reviews Drug Discovery.

[22]  C. Bailey,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet.

[23]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[24]  J. Gerich.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[25]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[26]  Antonio Pflüger,et al.  Executive Summary. , 2012, Journal of the ICRU.

[27]  S. Nair,et al.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.